SureSelect Cancer CGP Assay
SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability).
Receive your quote directly from the manufacturer.
SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability).
Powered by SureSelect XT HS2 library preparation and target enrichment chemistry, the assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.
- Globally curated gene content (679 genes for DNA, 80 genes for RNA) sourced from cancer databases and leading clinical cancer researchers
- Improved lab efficiency with automation, including the benchtop Agilent Magnis NGS Prep system that requires minimal expertise and only 15 minutes of hands-on time for walkaway convenience and the Agilent Bravo NGS workstation, a liquid handling platform for scaling up to 96 samples per run
- Enzymatic fragmentation option eliminates the need for physical shearing equipment
- Start with input as low as 10 ng DNA (recommended 50 ng) to enable profiling of more samples
- Fast hybridization (90 minutes) for library preparation in a single day
- Detection of de novo gene fusions (80 genes) requiring only one gene partner
- Developed for multiple sample types including FFPE
- Modular workflow allows the option to assay DNA and RNA separately or together in the same sequencing run
- Flexible data analysis options, including Agilent Alissa, customer in-house, and third-party software
Brochures
Tumor genomic profiling with Agilent SureSelect cancer assays
Agilent SureSelect cancer assays are a portfolio of targeted resequencing assays based on next-generation sequencing technology (NGS), which can be utilized in comprehensive genomic profiling (CGP) to advance precision oncology. SureSelect cancer assays enable you to detect key classes of somatic variants and assess immuno-oncology biomarkers and homologous recombination deficiency. Explore the benefits such as error-correcting molecular barcodes, convenient enzymatic fragmentation, and minimum sample input; plus, discover how the workflow solution can be configured to meet the specific needs of your laboratory.
More insights in sight: Comprehensive genomic profiling with SureSelect Cancer CGP Assay
In this product brochure, Agilent Technologies presents the SureSelect Cancer CGP Assay. The SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability). Powered by SureSelect XT HS2 library preparation and target enrichment chemistry, the assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.
Agilent SureSelect cancer custom panels
Agilent SureSelect Cancer Custom panels enable tumor genomic profiling with next-generation sequencing (NGS) panels customized to fit specific laboratory requirements, including the incorporation of new and emerging biomarkers. SureSelect Cancer Custom panels are combined with library preparation and target enrichment reagents to enable detection of all key classes of somatic changes, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/ deletions (indels), and translocations (TLs). Agilent Technologies highlights data demonstrating the high target coverage achieved by SureSelect Cancer Custom panels for assays; and their consistent detection of key somatic variant classes.
Agilent SureSelect cancer tumor-specific assays
Agilent SureSelect cancer tumor-specific assays offer genomic profiling of solid tumors with next-generation sequencing (NGS) panels for lung, colon, pancreas, bladder, and kidney. The panels are comprised of DNA modules of approximately 50 genes each for sequencing on Illumina® MiSeq™ and MiniSeq instruments, enabling tumor genomic profiling at a lower cost. Agilent demonstrates the target coverage and distribution uniformity of the assays, their consistent detection of key somatic variant classes, de novo gene fusion detection from just one gene partner, and variant detection from cell-free DNA (cfDNA) samples.
SureSelect Cancer CGP Assay: Comprehensive genomic profiling (CGP) to maximize tumor insights
In this data sheet, Agilent Technologies presents the SureSelect Cancer CGP Assay and highlights key advantages of this assay which offers comprehensive genomic profiling for solid tumors to maximize tumor insights. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability). Powered by SureSelect XT HS2 library preparation and target enrichment chemistry, the assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.
Comprehensive genomic profiling for cancer
Decoding the differences of cancer at a genomic level is key to precision oncology. Agilent's SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay and workflow detects biomarkers from solid tumors by profiling clinically relevant genes and assessing key classes of mutations to gain insights into tumors. The assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries.
Tools to advance precision oncology
Global Head of Medical Affairs at Agilent Technologies offers insights into the technologies driving the field of precision oncology
